Carboplatin, Pemetrexed and Bevacizumab — Competitive Intelligence Brief

Carboplatin, Pemetrexed and Bevacizumab (Carboplatin, Pemetrexed and Bevacizumab) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Platinum-based chemotherapy, Antifolate, Monoclonal antibody. Area: Oncology.

phase 2 Platinum-based chemotherapy, Antifolate, Monoclonal antibody DNA, Thymidylate synthase, VEGF-A Oncology Small molecule

Target snapshot

Carboplatin, Pemetrexed and Bevacizumab (Carboplatin, Pemetrexed and Bevacizumab) — Christiana Care Health Services. Carboplatin is a platinum-based chemotherapy drug that works by crosslinking DNA, thereby inhibiting cancer cell replication. Pemetrexed is an antifolate drug that inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase, leading to DNA synthesis inhibition. Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A), preventing angiogenesis.

Comparator set

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Carboplatin, Pemetrexed and Bevacizumab TARGET	Carboplatin, Pemetrexed and Bevacizumab	Christiana Care Health Services	phase 2	Platinum-based chemotherapy, Antifolate, Monoclonal antibody	DNA, Thymidylate synthase, VEGF-A

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Platinum-based chemotherapy, Antifolate, Monoclonal antibody class)

1. Christiana Care Health Services · 1 drug in this class